Using deep learning to predict tumor mutational burden from scans of H&E-stained multicenter slides of lung squamous cell carcinoma.
H&E
cancer
genetics
immunotherapy
lung cancer
tumor mutational burden
Journal
Journal of medical imaging (Bellingham, Wash.)
ISSN: 2329-4302
Titre abrégé: J Med Imaging (Bellingham)
Pays: United States
ID NLM: 101643461
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
06
09
2022
accepted:
16
01
2023
pmc-release:
21
02
2024
entrez:
24
2
2023
pubmed:
25
2
2023
medline:
25
2
2023
Statut:
ppublish
Résumé
A high tumor mutational burden (TMB) is a promising biomarker for identifying lung squamous cell carcinoma (SqCC) patients who are more likely to benefit from risky but potentially highly beneficial immunotherapy, but it is not available in most clinics. It has been shown that it is possible to predict TMB from standard-of-care cancer histology slides using deep learning for various cancer sites. Our goal is to build a model that can do this specifically for lung SqCC and to validate it on a held-out test set from centers on which the model was not trained. We obtained scans of diagnostic slides from 50 lung SqCC patients, with one slide per-patient, from 35 different centers. We held out 20 slides from 15 centers for testing and used the rest for training and validation, ensuring that no center was represented in more than one set. Using transfer learning, we explored several neural network architectures and training parameters to choose an optimal model. Using the training and validation sets, we found the optimal model to be VGG16. The per-patient AUC for this model on the held-out test set was 0.65, with an accuracy of 65%, true positive rate of 77%, and true negative rate of 43%. A deep learning model can predict TMB from scans of H&E-stained slides of lung SqCC resections on an independent test set containing images only from centers on which the model was not trained. With further development and external validation, such a system can act as an alternative to traditional genetic sequencing for patients with SqCC; this will help physicians determine, with more accuracy, whether patients should be given immunotherapy. This will more effectively give access to immunotherapy drugs to those who need them and help spare others the toxicities associated with them.
Identifiants
pubmed: 36825084
doi: 10.1117/1.JMI.10.1.017502
pii: 22229GR
pmc: PMC9941775
doi:
Types de publication
Journal Article
Langues
eng
Pagination
017502Informations de copyright
© 2023 Society of Photo-Optical Instrumentation Engineers (SPIE).
Références
Clin Epidemiol. 2011;3:139-48
pubmed: 21607015
Sci Rep. 2021 Aug 16;11(1):16605
pubmed: 34400666
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Expert Rev Anticancer Ther. 2013 Jun;13(6):745-58
pubmed: 23773106
Lancet Oncol. 2018 Apr;19(4):521-536
pubmed: 29545095
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Clin Cancer Res. 2019 Aug 1;25(15):4592-4602
pubmed: 30824587
J Gastroenterol. 2021 Jun;56(6):547-559
pubmed: 33909150
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
N Engl J Med. 2016 Sep 22;375(12):1109-12
pubmed: 27653561
ESMO Open. 2021 Oct;6(5):100273
pubmed: 34607285
J Clin Oncol. 2020 May 10;38(14):1505-1517
pubmed: 32150489
J Thorac Oncol. 2020 Oct;15(10):1657-1669
pubmed: 32599071